Lack of a specific effect of corticotropin-releasing hormone (CRH) on plasma levels of 13,14-dihydro-15-keto-prostaglandin E2 in normal subjects.
The responses of plasma adrenocorticotrophic hormone (corticotrophin, ACTH), cortisol and 13,14-dihydro-15-keto-prostaglandin E2 (PGE2-M), a stable metabolite of prostaglandin E2 (PGE2) to i.v. injection of corticotrophin-releasing hormone (CRH) were studied in eight healthy subjects before and after a dexamethasone suppression test. We demonstrated a slight increase in PGE2-M after CRH injection in a dose that markedly augmented ACTH and cortisol levels. CRH did not produce any significant changes in ACTH, cortisol or PGE2-M after dexamethasone treatment. The results did not confirm a specific effect of CRH on PGE2 production.
Zacharieva
S
S
Clinical Center of Endocrinology and Gerontology, Medical Academy, Sofia, Bulgaria.
Muchá
I
I
Wippermann
M
M
Sheitanova
S
S
Andonova
K
K
D000324:Adrenocorticotropic Hormone / Q000097:blood; D000328:Adult; D003346:Corticotropin-Releasing Hormone / Q000494:pharmacology*; D003907:Dexamethasone; D015232:Dinoprostone / Q000031:analogs & derivatives* / Q000097:blood; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007700:Kinetics; D008297:Male
C025087:15-keto-13,14-dihydroprostaglandin E2; D003907:Dexamethasone; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone; D015232:Dinoprostone; D006854:Hydrocortisone